Explore Moderna's Q3 2025 financial performance with detailed insights, including revenue trends, losses, and future recommendations for investors. Stay informed on mRNA market dynamics.
Explore Moderna's Q2 2025 financial report highlighting a net loss of $825M, cash decline, and deferred revenue growth. Investment recommendation: Hold.
Explore Moderna's Q1 2025 financial performance, revealing key sales, losses, and strategic recommendations for investors amid evolving market dynamics.
Explore Moderna, Inc.'s 2024 financial report highlighting $8.362B revenue, $3.607B loss, and R&D prospects. Investors advised to hold amid market challenges.
Discover crucial details from Moderna's 8-K filing on January 13, 2025, highlighting significant corporate events and insights for investors. Ticker: MRNA.
Explore BioNTech SE's financial report detailing a $467M royalty settlement with the University of Pennsylvania, including Pfizer's $170M reimbursement and key agreement terms.
Explore BioNTech SE's Form 6-K report detailing a $791.5M settlement with the NIH over COVID-19 vaccine royalties and new licensing terms effective January 2024.